

Using health technology assessment to assess the value
systematic review and expert consultation across eight

European Journal of Health Economics

19, 123-152

DOI: 10.1007/s10198-017-0871-0

Citation Report

#	ARTICLE	IF	CITATIONS
1	Multiple Criteria Decision Analysis (MCDA) for evaluating new medicines in Health Technology Assessment and beyond: The Advance Value Framework. <i>Social Science and Medicine</i> , 2017, 188, 137-156.	3.8	135
2	Multiple criteria decision analysis in the context of health technology assessment: a simulation exercise on metastatic colorectal cancer with multiple stakeholders in the English setting. <i>BMC Medical Informatics and Decision Making</i> , 2017, 17, 149.	3.0	23
3	Limitations of Traditional Health Technology Assessment Methods and Implications for the Evaluation of Innovative Therapies. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
4	Using multi-criteria decision analysis to appraise orphan drugs: a systematic review. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2018, 18, 135-146.	1.4	18
5	Valuing health states: is the MACBETH approach useful for valuing EQ-5D-3L health states?. <i>Health and Quality of Life Outcomes</i> , 2018, 16, 235.	2.4	4
6	Evaluating the Benefits of New Drugs in Health Technology Assessment Using Multiple Criteria Decision Analysis: A Case Study on Metastatic Prostate Cancer With the Dental and Pharmaceuticals Benefits Agency (TLV) in Sweden. <i>MDM Policy and Practice</i> , 2018, 3, 238146831879621.	0.9	5
7	Comparing Use of Health Technology Assessment in Pharmaceutical Policy among Earlier and More Recent Adopters in the European Union. <i>Value in Health Regional Issues</i> , 2018, 16, 81-91.	1.2	23
8	Determining the Value of Two Biologic Drugs for Chronic Inflammatory Skin Diseases: Results of a Multi-Criteria Decision Analysis. <i>BioDrugs</i> , 2018, 32, 281-291.	4.6	15
9	Health Technology Assessment and Its Use in Drug Policies: Singapore. <i>Value in Health Regional Issues</i> , 2019, 18, 176-183.	1.2	16
11	Cost-Effectiveness of Sacubitril/Valsartan in Germany: An Application of the Efficiency Frontier. <i>Value in Health</i> , 2019, 22, 1119-1127.	0.3	13
12	Willingness to pay for QALY: perspectives and contexts in Japan. <i>Journal of Medical Economics</i> , 2019, 22, 1041-1046.	2.1	18
13	Innovation as a value in healthcare priority-setting: the UK experience. <i>Social Justice Research</i> , 2019, 32, 208-238.	1.1	24
14	Multicriteria Decision Analysis to Support Health Technology Assessment Agencies: Benefits, Limitations, and the Way Forward. <i>Value in Health</i> , 2019, 22, 1283-1288.	0.3	97
15	Doenças raras, drogas órfãs e as políticas para avaliação e incorporação de tecnologias nos sistemas de saúde. <i>Sociologias</i> , 2019, 21, 332-364.	0.3	7
16	Assessing the Joint Value of Genomic-Based Diagnostic Tests and Gene Therapies. <i>Journal of Personalized Medicine</i> , 2019, 9, 28.	2.5	6
17	Alternative access schemes for pharmaceuticals in Europe: Towards an emerging typology. <i>Health Policy</i> , 2019, 123, 630-634.	3.0	9
18	Multi-criteria decision analysis for health technology assessment: addressing methodological challenges to improve the state of the art. <i>European Journal of Health Economics</i> , 2019, 20, 891-918.	2.8	45
19	The price of innovation - the role of drug pricing in financing pharmaceutical innovation. A conceptual framework. <i>Journal of Market Access & Health Policy</i> , 2019, 7, 1583536.	1.5	13

#	ARTICLE	IF	CITATIONS
20	Addressing Health System Values in Health Technology Assessment: The Use of Evidence-Informed Deliberative Processes. International Journal of Technology Assessment in Health Care, 2019, 35, 82-84.	0.5	9
21	Determinants of price negotiations for new drugs. The experience of the Italian Medicines Agency. Health Policy, 2019, 123, 595-600.	3.0	30
22	Quantifying Preferences in Drug Benefit-Risk Decisions. Clinical Pharmacology and Therapeutics, 2019, 106, 955-959.	4.7	19
23	Use of medicine pricing and reimbursement policies for universal health coverage in Indonesia. PLoS ONE, 2019, 14, e0212328.	2.5	14
24	Shedding light on the HTA consultancy market: Insights from Poland. Health Policy, 2019, 123, 1237-1243.	3.0	4
25	Critical Review of European Health-Economic Guidelines for the Health Technology Assessment of Medical Devices. Frontiers in Medicine, 2019, 6, 278.	2.6	23
26	The implementation of HTA in medicine pricing and reimbursement policies in Indonesia: Insights from multiple stakeholders. PLoS ONE, 2019, 14, e0225626.	2.5	6
27	Regenerative Medicine and Cell Therapy in Orthopedics”Health Policy, Regulatory and Clinical Development, and Market Access. Techniques in Orthopaedics, 2019, 34, 224-243.	0.2	4
28	Value assessment of disease-modifying therapies for Relapsing-Remitting Multiple Sclerosis: HTA evidence from seven OECD countries. Health Policy, 2019, 123, 118-129.	3.0	6
29	Is the National Institute for Health and Care Excellence (NICE) in England more “innovation-friendly” than the Federal Joint Committee (G-BA) in Germany?. Expert Review of Pharmacoeconomics and Outcomes Research, 2019, 19, 453-462.	1.4	4
30	Advanced therapy medicinal products and health technology assessment principles and practices for value-based and sustainable healthcare. European Journal of Health Economics, 2019, 20, 427-438.	2.8	85
31	Evaluation of new medicines in Spain and comparison with other European countries. Gaceta Sanitaria, 2020, 34, 133-140.	1.5	18
32	Economic Evaluation for Pricing and Reimbursement of New Drugs in Spain: Fable or Desideratum?. Value in Health, 2020, 23, 25-31.	0.3	7
33	Multiple Criteria Decision Analysis for HTA across four EU Member States: Piloting the Advance Value Framework. Social Science and Medicine, 2020, 246, 112595.	3.8	23
34	HTA for pharmaceuticals in Europe: will the mountain deliver a mouse?. European Journal of Health Economics, 2020, 21, 1-5.	2.8	4
35	Valuing Health State: An EQ-5D-5L Value Set for Ethiopians. Value in Health Regional Issues, 2020, 22, 7-14.	1.2	50
36	Access to medicines - a systematic review of the literature. Research in Social and Administrative Pharmacy, 2020, 16, 1166-1176.	3.0	10
37	Holistic cost-effectiveness analysis of anticancer drug regimens in Japan. Drug Discovery Today, 2020, 25, 269-273.	6.4	4

#	ARTICLE	IF	CITATIONS
38	Promotion of mental health in young adults via mobile phone app: study protocol of the ECoWeB (emotional competence for well-being in Young adults) cohort multiple randomised trials. BMC Psychiatry, 2020, 20, 458.	2.6	22
39	Recalibrating Health Technology Assessment Methods for Cell and Gene Therapies. Pharmacoeconomics, 2020, 38, 1297-1308.	3.3	23
40	Impact of Research and Development Strategy on Sustainable Growth in Multinational Pharmaceutical Companies. Sustainability, 2020, 12, 5358.	3.2	10
41	International Experience in Therapeutic Value and Value-Based Pricing: A Rapid Review of the Literature. Value in Health Regional Issues, 2020, 23, 37-48.	1.2	10
42	The Methodological Quality and Challenges in Conducting Economic Evaluations of Newborn Screening: A Scoping Review. International Journal of Neonatal Screening, 2020, 6, 94.	3.2	6
43	The political economics of cancer drug discovery and pricing. Drug Discovery Today, 2020, 25, 2149-2160.	6.4	10
44	Health-related quality of life, work productivity and costs related to patients with inflammatory bowel disease in Austria. Journal of Medical Economics, 2020, 23, 1061-1071.	2.1	12
45	ICER Value Framework 2020 Update: Recommendations on the Aggregation of Benefits and Contextual Considerations. Value in Health, 2020, 23, 1040-1048.	0.3	13
47	Results dissemination of registered clinical trials across Polish academic institutions: a cross-sectional analysis. BMJ Open, 2020, 10, e034666.	1.9	11
48	Access to Medicines, Access to Markets. Frontiers in Sociology, 2020, 5, 58.	2.0	1
49	Early Health Technology Assessment during Nonalcoholic Steatohepatitis Drug Development: A Two-Round, Cross-Country, Multicriteria Decision Analysis. Medical Decision Making, 2020, 40, 830-845.	2.4	8
50	Companies'™ Health Technology Assessment Strategies and Practices in Australia, Canada, England, France, Germany, Italy and Spain: An Industry Metrics Study. Frontiers in Pharmacology, 2020, 11, 594549.	3.5	12
51	Improving Interactions Between Health Technology Assessment Bodies and Regulatory Agencies: A Systematic Review and Cross-Sectional Survey on Processes, Progress, Outcomes, and Challenges. Frontiers in Medicine, 2020, 7, 582634.	2.6	15
52	A novel valuation model for medical intervention development based on progressive dynamic changes that integrates Health Technology Assessment outcomes with early-stage innovation and indication-specific clinical success rates. Journal of Innovation and Entrepreneurship, 2020, 9, .	4.0	4
53	Health Preference Research in Europe: A Review of Its Use in Marketing Authorization, Reimbursement, and Pricing Decisions"Report of the ISPOR Stated Preference Research Special Interest Group. Value in Health, 2020, 23, 831-841.	0.3	37
54	Assessment of technical errors and validation processes in economic models submitted by the company for NICE technology appraisals. International Journal of Technology Assessment in Health Care, 2020, 36, 311-316.	0.5	3
55	A cost analysis of SIR-Spheres yttrium-90 resin microspheres versus tyrosine kinase inhibitors in the treatment of unresectable hepatocellular carcinoma in France, Italy, Spain and the UK. Journal of Medical Economics, 2020, 23, 593-602.	2.1	10
56	Development of the WHO-INTEGRATE evidence-to-decision framework: an overview of systematic reviews of decision criteria for health decision-making. Cost Effectiveness and Resource Allocation, 2020, 18, 8.	1.5	27

#	ARTICLE	IF	CITATIONS
57	International Strategy for Sustainable Growth in Multinational Pharmaceutical Companies. Sustainability, 2020, 12, 867.	3.2	14
58	Association Between the Use of Surrogate Measures in Pivotal Trials and Health Technology Assessment Decisions: A Retrospective Analysis of NICE and CADTH Reviews of Cancer Drugs. Value in Health, 2020, 23, 319-327.	0.3	15
59	Peer Review and Transparency in Evidence-Source Selection in Value and Health Technology Assessment. Value in Health, 2020, 23, 689-696.	0.3	2
60	Added Therapeutic Value of Medicinal Products for French and German Health Technology Assessment Organizations: A Systematic Comparison. Value in Health, 2021, 24, 346-352.	0.3	8
61	A Health Opportunity Cost Threshold for Cost-Effectiveness Analysis in the United States. Annals of Internal Medicine, 2021, 174, 25-32.	3.9	103
62	Patient access to gene therapy medicinal products: a comprehensive review. BMJ Innovations, 2021, 7, 123-134.	1.7	8
63	Evidence-Based Decision Making 3: Health Technology Assessment. Methods in Molecular Biology, 2021, 2249, 429-454.	0.9	1
64	Multiple criteria decision analysis for medicine reimbursement in the Lebanese context. International Journal of Technology Assessment in Health Care, 2021, 37, .	0.5	0
65	Cost of hemophilia A in Turkey: an economic disease burden analysis. Journal of Medical Economics, 2021, 24, 1052-1059.	2.1	4
66	Evidence of a disability paradox in patient-reported outcomes in haemophilia. Haemophilia, 2021, 27, 245-252.	2.1	25
67	Assessing social preferences in reimbursement negotiations for new Pharmaceuticals in Oncology: an experimental design to analyse willingness to pay and willingness to accept. BMC Health Services Research, 2021, 21, 234.	2.2	4
68	The use of "added benefit"™ to determine the price of new anti-cancer drugs in France, 2004-2017. European Journal of Cancer, 2021, 145, 11-18.	2.8	13
69	Bridging the gap: Can International Consortium of Health Outcomes Measurement standard sets align outcomes accepted for regulatory and health technology assessment decision-making of oncology medicines. Pharmacology Research and Perspectives, 2021, 9, e00742.	2.4	9
70	Value-based decision-making for orphan drugs with multiple criteria decision analysis: burosumab for the treatment of X-linked hypophosphatemia. Current Medical Research and Opinion, 2021, 37, 1021-1030.	1.9	2
71	Time to define common European criteria for therapeutic added value. Therapie, 2021, , .	1.0	0
72	The Role of Patient Experience in the Value Assessment of Complex Technologies " Do HTA Bodies Need to Reconsider How Value is Assessed?. Health Policy, 2021, 125, 593-601.	3.0	11
73	Institute for Clinical and Economic Review. , 2021, , 112-141.		0
74	Pharmaceutical Camel Products; Marketing Strategies for Successful International Penetration. Indian Journal of Pharmaceutical Education and Research, 2021, 55, 629-637.	0.6	0

#	ARTICLE	IF	CITATIONS
75	Value-based care: a good idea, many caveats. European Journal of Public Health, 2021, 31, 676-677.	0.3	1
76	A systematic review of pharmaceutical price mark-up practice and its implementation. Exploratory Research in Clinical and Social Pharmacy, 2021, 2, 100020.	1.0	3
77	Analysis of the Household and Health Care System Expenditures in Bulgaria. Frontiers in Public Health, 2021, 9, 675277.	2.7	3
78	Health technology assessment through the six sigma approach in abdominoplasty: Scalpel vs electrosurgery. Medical Engineering and Physics, 2021, 93, 27-34.	1.7	4
79	A Review of Current Approaches to Defining and Valuing Innovation in Health Technology Assessment. Value in Health, 2021, 24, 1773-1783.	0.3	6
80	Realising the broader value of vaccines in the UK. Vaccine: X, 2021, 8, 100096.	2.1	12
81	Value drivers for pharmaceutical products in health technology assessment (HTA) in Saudi Arabia: Results from a capacity Building, Multi-Stakeholder workshop. Saudi Pharmaceutical Journal, 2021, 29, 946-954.	2.7	7
82	Reimagining Pharmaceutical Market Exclusivities: Should the Duration of Guaranteed Monopoly Periods Be Value Based?. Value in Health, 2021, 24, 1328-1334.	0.3	8
83	Health technology assessment (HTA) in England, France and Germany: what do matched drug pairs tell us about recommendations by national HTA agencies?. Journal of Comparative Effectiveness Research, 2021, 10, 1187-1195.	1.4	7
84	Social media mining in drug development—Fundamentals and use cases. Drug Discovery Today, 2021, 26, 2871-2880.	6.4	9
85	A Six Sigma DMAIC methodology as a support tool for Health Technology Assessment of two antibiotics. Mathematical Biosciences and Engineering, 2021, 18, 3469-3490.	1.9	22
86	HTA Reshaping: Rethinking the Health Technology Assessment Framework in Portugal. Portuguese Journal of Public Health, 2021, 39, 36-47.	0.5	1
88	Common Problems, Common Data Model Solutions: Evidence Generation for Health Technology Assessment. Pharmacoeconomics, 2021, 39, 275-285.	3.3	42
90	Health Technology Assessment of Advanced Therapy Medicinal Products: Comparison Among 3 European Countries. Frontiers in Pharmacology, 2021, 12, 755052.	3.5	13
91	Gesundheitsökonomische Evaluation. The Springer Reference Pflege, Gesundheit, 2019, , 669-680.	0.3	1
92	Health technology assessment and reimbursement of pharmaceuticals in Italy. Farmakoekonomika, 2019, 12, 156-164.	1.2	1
93	A multi-stakeholder approach in optimising patients'™ needs in the benefit assessment process of new metastatic breast cancer treatments. Breast, 2020, 52, 78-87.	2.2	7
94	An Exploratory Analysis of Predictors of Concordance Between Canadian Common Drug Review Reimbursement Recommendations and the Subsequent Decisions by Ontario, British Columbia and Alberta. Healthcare Policy, 2020, 15, 90-101.	0.6	2

#	ARTICLE	IF	CITATIONS
95	Should Health Economic Evaluations Undertaken from a Societal Perspective Include Net Government Spending Multiplier Effects?. Applied Health Economics and Health Policy, 2020, 18, 467-475.	2.1	1
96	Access to medicines in Turkey: Evaluation of the process of medicines brought from abroad. International Journal of Technology Assessment in Health Care, 2020, 36, 585-591.	0.5	1
97	Decision-making in the midst of uncertainty: appraising expensive medicines in England. Ciencia E Saude Coletiva, 2021, 26, 5523-5531.	0.5	0
98	Similarities and Differences in Health Technology Assessment Systems and Implications for Coverage Decisions: Evidence from 32 Countries. PharmacoEconomics - Open, 2022, 6, 315-328.	1.8	22
100	Identifying institutional barriers when implementing new technologies in the healthcare industry. European Journal of Innovation Management, 2023, 26, 909-932.	4.6	10
101	Paths towards Universal Health Coverage: beyond political commitments. Journal of Global Health, 2021, 11, 16002.	2.7	1
102	How innovation can be defined, evaluated and rewarded in health technology assessment. Health Economics Review, 2022, 12, 1.	2.0	16
103	Addressing uncertainty in relative effectiveness assessments by HTA organizations. International Journal of Technology Assessment in Health Care, 2022, 38, e17.	0.5	3
104	Promoting innovation while controlling cost: The UK's approach to health technology assessment. Health Policy, 2022, 126, 224-233.	3.0	7
105	Report of the Lancet Commission on the Value of Death: bringing death back into life. Lancet, The, 2022, 399, 837-884.	13.7	197
106	How value-based policy interventions influence price negotiations for new medicines: An experimental approach and initial evidence. Health Policy, 2022, 126, 112-121.	3.0	2
107	HTA Training for Healthcare Professionals: International Overview of Initiatives Provided by HTA Agencies and Organizations. Frontiers in Public Health, 2022, 10, 795763.	2.7	5
108	Access to Innovative Neurological Drugs in Europe: Alignment of Health Technology Assessments Among Three European Countries. Frontiers in Pharmacology, 2021, 12, 823199.	3.5	4
109	Early Access to Medicines: Use of Multicriteria Decision Analysis (MCDA) as a Decision Tool in Catalonia (Spain). Journal of Clinical Medicine, 2022, 11, 1353.	2.4	5
110	Mapping Canadian Data Assets to Generate Real-World Evidence: Lessons Learned from Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration's RWE Data Working Group. Current Oncology, 2022, 29, 2046-2063.	2.2	2
111	The (Harsh) Reality of Real-World Data External Comparators for Health Technology Assessment. Value in Health, 2022, 25, 1253-1256.	0.3	3
112	Health technology assessments and real-world evidence: tell us what you want, what you really, really want. Journal of Comparative Effectiveness Research, 2022, 11, 297-299.	1.4	1
113	Cost Analysis of Platelet Transfusion in Italy for Patients with Chronic Liver Disease and Associated Thrombocytopenia Undergoing Elective Procedures. ClinicoEconomics and Outcomes Research, 2022, Volume 14, 205-220.	1.9	2

#	ARTICLE	IF	CITATIONS
114	Strengthening the Interface of Evidence-Based Decision Making Across European Regulators and Health Technology Assessment Bodies. <i>Value in Health</i> , 2022, 25, 1726-1735.	0.3	8
115	Enhancing access to innovative cancer drugs: Cross-sector consensus on a way forward to benefit patients. <i>Drug Discovery Today</i> , 2022, 27, 946-950.	6.4	1
116	Multicriteria decision analysis in health care decision in oncology: a systematic review. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2022, 22, 365-380.	1.4	3
117	Assessing the value contribution of bimekizumab for the treatment of moderate-to-severe psoriasis using a multidisciplinary reflective multi-criteria decision analysis. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2022, 22, 941-953.	1.4	3
118	Is Value Portable? An Examination of Contextual and Practical Considerations that Affect the Transferability of Value Assessments between Settings. <i>International Journal of Technology Assessment in Health Care</i> , 2022, , 1-26.	0.5	0
121	Mapping Outcomes and Registries Used in Current Danish Pharmacoepidemiological Research. <i>Clinical Epidemiology</i> , 2022, Volume 14, 521-542.	3.0	4
122	Coverage of New Drugs in Medicare Part D. <i>Milbank Quarterly</i> , 2022, 100, 562-588.	4.4	3
123	FEASIBILITY STUDY TO CHARACTERISE P&R DECISION-MAKING CRITERIA FOR THE INCLUSION OF NEW DRUGS IN THE SPANISH NHS: THE CEFIDEROLOC EXAMPLE. <i>International Journal of Technology Assessment in Health Care</i> , 2022, , 1-25.	0.5	2
124	Framework Development for Clinical Comprehensive Evaluation of Drugs—a Study Protocol Using the Delphi Method and Analytic Hierarchy Process. <i>Frontiers in Pharmacology</i> , 2022, 13, .	3.5	2
125	Multiple Criteria Decision Analysis (MCDA) for evaluating cancer treatments in hospital-based health technology assessment: The Paraconsistent Value Framework. <i>PLoS ONE</i> , 2022, 17, e0268584.	2.5	5
126	Using the Dynamic SWOT Analysis to Assess Options for Implementing the HB-HTA Model. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 7281.	2.6	3
127	Does health technology assessment compromise access to pharmaceuticals?. <i>European Journal of Health Economics</i> , 2023, 24, 437-451.	2.8	2
128	Differences in Evidentiary Requirements Between European Medicines Agency and European Health Technology Assessment of Oncology Drugs—Can Alignment Be Enhanced?. <i>Value in Health</i> , 2022, 25, 1958-1966.	0.3	6
129	Market access for medicines treating rare diseases: Association between specialised processes for orphan medicines and funding recommendations. <i>Social Science and Medicine</i> , 2022, 306, 115119.	3.8	6
130	Systematic literature review on implicit factors influencing the HTA deliberative processes in Europe. <i>Journal of Market Access & Health Policy</i> , 2022, 10, .	1.5	0
131	Appraising Drugs Based on Cost-effectiveness and Severity of Disease in Norwegian Drug Coverage Decisions. <i>JAMA Network Open</i> , 2022, 5, e2219503.	5.9	3
132	Value and Price of Multi-indication Cancer Drugs in the USA, Germany, France, England, Canada, Australia, and Scotland. <i>Applied Health Economics and Health Policy</i> , 2022, 20, 757-768.	2.1	22
134	How do HTA agencies perceive conditional approval of medicines? Evidence from England, Scotland, France and Canada. <i>Health Policy</i> , 2022, 126, 1130-1143.	3.0	4

#	ARTICLE	IF	CITATIONS
135	An Economic Evaluation of the Adjuvanted Quadrivalent Influenza Vaccine Compared with Standard-Dose Quadrivalent Influenza Vaccine in the Spanish Older Adult Population. <i>Vaccines</i> , 2022, 10, 1360.	4.4	4
136	Need for HTA supported risk factor screening for hypertension and diabetes in Nepal: A systematic scoping review. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	2.4	4
137	Towards a European harmonization of health technology assessment recommendations executive paper of European regulatory conference focused on the EU commission proposal to harmonize HTA. <i>Frontiers in Drug Safety and Regulation</i> , 0, 2, .	1.8	3
138	How can we optimise health technology assessment and reimbursement decisions to accelerate access to new cardiovascular medicines?. <i>International Journal of Cardiology</i> , 2022, 365, 61-68.	1.7	2
139	Análisis del proceso de Evaluación de Tecnologías Sanitarias del Sistema de Protección Financiera Para Diagnósticos y Tratamientos de Alto Costo en Chile (Ley Ricarte Soto). <i>Value in Health Regional Issues</i> , 2022, 32, 95-101.	1.2	2
140	A Review on Existing Health Technology Assessment (HTA) Methodologies. <i>International Journal of Health Systems and Translational Medicine</i> , 2022, 2, 1-27.	0.1	0
141	A call to action to harmonize patient-reported outcomes evidence requirements across key European HTA bodies in oncology. <i>Future Oncology</i> , 2022, 18, 3323-3334.	2.4	1
142	Psychometric evaluation of the Mental Health Quality of Life (MHQoL) instrument in seven European countries. <i>Health and Quality of Life Outcomes</i> , 2022, 20, .	2.4	3
143	Value assessment of medicinal products by the Italian Medicines Agency (AIFA) and French National Authority for Health (HAS): Similarities and discrepancies. <i>Frontiers in Medical Technology</i> , 0, 4, .	2.5	1
144	Investigating patients' preferences for new anti-diabetic drugs to inform public health insurance coverage decisions: a discrete choice experiment in China. <i>BMC Public Health</i> , 2022, 22, .	2.9	0
145	A systematic review of the early dialogue frameworks used within health technology assessment and their actual adoption from HTA agencies. <i>Frontiers in Public Health</i> , 0, 10, .	2.7	1
146	Impact of health technology assessment implementation with a special focus on middle-income countries. <i>Health Policy and Technology</i> , 2022, 11, 100688.	2.5	2
147	Gesundheitsökonomische Evaluation. <i>The Springer Reference Pflege, Gesundheit</i> , 2022, , 779-790.	0.3	0
148	Integrating organizational impacts into health technology assessment (HTA): an analysis of the content and use of existing evaluation frameworks. <i>International Journal of Technology Assessment in Health Care</i> , 2022, 38, .	0.5	3
149	Endpoints for safety in health technology assessments – The experiences of the Danish Medicines Council. <i>Health Policy and Technology</i> , 2022, 11, 100692.	2.5	0
150	Cancer treatments touch a wide range of values that count for patients and other stakeholders: What are the implications for decision-making?. <i>Cancer Medicine</i> , 0, , .	2.8	3
151	Characterizing attributes of innovation of technologies for healthcare: a systematic review. <i>Journal of Medical Economics</i> , 2022, 25, 1158-1166.	2.1	2
152	Ergebnisse des AMNOG-Erstattungsbetragsverfahrens. , 2022, , 257-277.		0

#	ARTICLE	IF	CITATIONS
153	Pharmaceutical policies for gaining access to high-priced medicines: a comparative analysis between England and Brazil. <i>SaÃºde Em Debate</i> , 2022, 46, 886-905.	0.5	0
154	The Value of New: Consideration of Product Novelty in Health Technology Assessments of Pharmaceuticals. <i>Applied Health Economics and Health Policy</i> , 0, , .	2.1	0
155	Financing and Reimbursement of Approved Advanced Therapies in Several European Countries. <i>Value in Health</i> , 2023, 26, 841-853.	0.3	7
156	Decision Criteria for Partial Nationalization of Pharmaceutical Supply Chain: A Scoping Review. <i>Economies</i> , 2023, 11, 25.	2.5	0
158	HTA Barriers for Conditional Approval Drugs. <i>Pharmacoeconomics</i> , 2023, 41, 529-545.	3.3	2
159	Health Technology Assessmentâ€“Informed Decision Making by the Federal Joint Committee/Institute for Quality and Efficiency in Health Care in Germany and the National Institute for Health and Care Excellence in England: The Role of Budget Impact. <i>Value in Health</i> , 2023, 26, 1032-1044.	0.3	0
160	The role of drug regulatory authorities and health technology assessment agencies in shaping incentives for antibiotic R&D: a qualitative study. <i>Journal of Pharmaceutical Policy and Practice</i> , 2023, 16, .	2.4	2
161	Added Therapeutic Benefit of Top-Selling Brand-name Drugs in Medicare. <i>JAMA - Journal of the American Medical Association</i> , 2023, 329, 1283.	7.4	11
162	Feasibility for pricing, budget allocation, and reimbursement of personalized medicine interventions. , 2023, , 135-148.		0
163	Expected Benefits and Challenges of Using Economic Evaluations to Make Decisions About the Content of Newborn Screening Programs in Vietnam: A Scoping Review of the Literature. <i>Journal of Inborn Errors of Metabolism and Screening</i> , 0, 11, .	0.3	0
164	Best practice considerations on the assessment of robotic assisted surgical systems: results from an international consensus expert panel. <i>International Journal of Technology Assessment in Health Care</i> , 2023, 39, .	0.5	1
165	The Beneluxa Initiative Domain Task Force HTA: A Comparison of Member Countriesâ€™ Past Health Technology Assessments. <i>International Journal of Technology Assessment in Health Care</i> , 0, , 1-24.	0.5	0
166	Algorithms and heuristics of health technology assessments: A retrospective analysis of factors associated with HTA outcomes for new drugs across seven OECD countries. <i>Social Science and Medicine</i> , 2023, 331, 116045.	3.8	3
167	The therapeutic value of treatment for multiple sclerosis: analysis of health technology assessments of three European countries. <i>Frontiers in Pharmacology</i> , 0, 14, .	3.5	0
168	Real-world evidence on the economic implications of CGRP-mAbs as preventive treatment of migraine. <i>BMC Neurology</i> , 2023, 23, .	1.8	7
169	Interface policies bridging outpatient and hospital sectors in Europe: can cross-sectorial collaboration in reimbursement and procurement improve access to affordable medicines?. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 0, , 1-12.	1.4	1
170	Cancer Drugs Reimbursed with Limited Evidence on Overall Survival and Quality of Life: Do Follow-Up Studies Confirm Patient Benefits?. <i>Clinical Drug Investigation</i> , 2023, 43, 621-633.	2.2	3
172	How to create value with constrained budgets in oncological care? A narrative review. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 0, , 1-11.	1.4	0

#	ARTICLE	IF	CITATIONS
173	How to price drugs reasonably?. Annals of Allergy, Asthma and Immunology, 2023, 131, 400.	1.0	0
174	The functions of known to be inaccurate prices in markets: A cross-country comparison of pharmaceutical list pricing. Journal of Business Research, 2023, 167, 114193.	10.2	0
175	Measuring the Uptake of Pharmacoepidemiologic Research Through Qualitative Analysis of Citations: A Case Study from a Canadian Network of Researchers. Science and Technology Libraries, 0, , 1-16.	1.8	0
176	We need to talk about values: a proposed framework for the articulation of normative reasoning in health technology assessment. Health Economics, Policy and Law, 0, , 1-21.	1.8	3
177	Pipeline progress and portfolio management of the top 30 pharma companies over the past two decades. Journal of Pharmaceutical Policy and Practice, 2023, 16, .	2.4	0
178	Differences in evidentiary requirements for oncology drug effectiveness assessments among six European health technology assessment bodies â€” can alignment be improved?. Expert Review of Pharmacoeconomics and Outcomes Research, 2024, 24, 251-265.	1.4	0
179	Proposing a health-specific organizational impact framework to evaluate organizational impacts in health technology assessments. International Journal of Technology Assessment in Health Care, 2023, 39, .	0.5	0
180	Shaping a suitable EU HTA dossier template: why the German template is not fit for purpose. European Journal of Health Economics, 0, , .	2.8	0
181	Scientific generalization of approaches to the development of the Health Technology Assessment system in international practice. Farmatsevtichnyi Zhurnal, 2023, , 46-61.	0.4	0
182	How can health technology assessment be improved to optimise access to medicines? Results from a Delphi study in Europe. European Journal of Health Economics, 0, , .	2.8	0
183	Estimating the cost-effectiveness threshold of advanced non-small cell lung cancer in China using mean opportunity cost and contingent valuation method. Cost Effectiveness and Resource Allocation, 2023, 21, .	1.5	0
184	Priority setting for health technology adoption at the national level: Lessons learned over 25Âyearsâ€™ experience. International Journal of Technology Assessment in Health Care, 2023, 39, .	0.5	0
185	Ranking Decision-Making Criteria for Early Adoption of Innovative Surgical Technologies. JAMA Network Open, 2023, 6, e2343703.	5.9	0
186	Implicit factors influencing the HTA deliberative processes in 5 European countries: results from a mixed-methods research. Health Policy OPEN, 2023, 5, 100109.	1.5	0
187	Can Drug Price Controls Help Patients Get a Better Deal? A SWOT Analysis. , 2023, 19, 222-233.		0
188	The Critical Intersect of Regulations, Health Technology Assessment, and Drug Safety Assessments. Drug Safety, 0, , .	3.2	0
189	DIGITAL DECISION-MAKING TOOLS IN THE FIELD OF PUBLIC ADMINISTRATION OF HEALTHCARE. Financial and Credit Activity Problems of Theory and Practice, 2023, 6, 528-540.	0.7	0
190	A Review of Current Approaches to Evaluating and Reimbursing New Medicines in a Subset of OECD Countries. Applied Health Economics and Health Policy, 2024, 22, 297-313.	2.1	0

#	ARTICLE	IF	CITATIONS
191	Evaluation of antibody-based preventive alternatives for respiratory syncytial virus: a novel multi-criteria decision analysis framework and assessment of nirsevimab in Spain. BMC Infectious Diseases, 2024, 24, .	2.9	0
192	AOTMiT reimbursement recommendations compared to other HTA agencies. European Journal of Health Economics, 0, .	2.8	0
193	Value-based pricing: a potential solution to difficult pricing discussions and payersâ€™ negotiations. Journal of Medical Economics, 2024, 27, 344-347.	2.1	1
194	Artificial Intelligence to Automate Network Meta-Analyses: Four Case Studies to Evaluate the Potential Application of Large Language Models. PharmacoEconomics - Open, 2024, 8, 205-220.	1.8	0
195	Artificial Intelligence to Automate Health Economic Modelling: A Case Study to Evaluate the Potential Application of Large Language Models. PharmacoEconomics - Open, 2024, 8, 191-203.	1.8	0
196	Use of Efficiency Frontiers to Align Prices and Clinical Benefits of Biologic Therapies for Plaque Psoriasis. JAMA Dermatology, 2024, 160, 409.	4.1	0
197	Assessment of quality of data submitted for NICE technology appraisals over two decades. BMJ Open, 2024, 14, e074341.	1.9	0
198	Priority-setting for hospital funding of high-cost innovative drugs and therapeutics: A qualitative institutional case study. PLoS ONE, 2024, 19, e0300519.	2.5	0